160 related articles for article (PubMed ID: 23640119)
1. Acute and sub-acute effect of ferric carboxymaltose on inflammation and adhesion molecules in patients with predialysis chronic renal failure.
Prats M; Font R; García-Ruiz C; Cabré C; Muñoz-Cortés M; Nogués MR; Jariod M; Romeu M; Martínez-Vea A
Nefrologia; 2013; 33(3):355-61. PubMed ID: 23640119
[TBL] [Abstract][Full Text] [Related]
2. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
Geisser P; Rumyantsev V
Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
[TBL] [Abstract][Full Text] [Related]
5. Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design.
Szczech LA; Bregman DB; Harrington RA; Morris D; Butcher A; Koch TA; Goodnough LT; Wolf M; Onken JE
Nephrol Dial Transplant; 2010 Jul; 25(7):2368-75. PubMed ID: 20466657
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
Bailie GR
Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930
[TBL] [Abstract][Full Text] [Related]
7. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
Charytan C; Bernardo MV; Koch TA; Butcher A; Morris D; Bregman DB
Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534
[TBL] [Abstract][Full Text] [Related]
8. Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial.
Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Meier Y; Larroque S; Roger SD;
BMC Nephrol; 2017 Jan; 18(1):24. PubMed ID: 28095881
[TBL] [Abstract][Full Text] [Related]
9. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
[TBL] [Abstract][Full Text] [Related]
10. [Clinical experience with ferric carboxymaltose in non-dialysis chronic kidney disease].
Minutolo R; Liberti ME; Garofalo C; Pacilio M; Sagliocchi A; Sguazzo A; Scarpati L; Sagliocca A; Santangelo S; Provenzano M; Savino M; Conte G; De Nicola L
G Ital Nefrol; 2015; 32(5):. PubMed ID: 26480261
[TBL] [Abstract][Full Text] [Related]
11. Ferric carboxymaltose in patients with heart failure and iron deficiency.
Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
[TBL] [Abstract][Full Text] [Related]
12. The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study.
Van Craenenbroeck EM; Conraads VM; Greenlaw N; Gaudesius G; Mori C; Ponikowski P; Anker SD
Eur J Heart Fail; 2013 Jul; 15(7):756-62. PubMed ID: 23639779
[TBL] [Abstract][Full Text] [Related]
13. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.
Beigel F; Löhr B; Laubender RP; Tillack C; Schnitzler F; Breiteneicher S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
Digestion; 2012; 85(1):47-54. PubMed ID: 22179489
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients.
Grimmelt AC; Cohen CD; Fehr T; Serra AL; Wuethrich RP
Clin Nephrol; 2009 Feb; 71(2):125-9. PubMed ID: 19203504
[TBL] [Abstract][Full Text] [Related]
15. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study.
Covic A; Mircescu G
Nephrol Dial Transplant; 2010 Aug; 25(8):2722-30. PubMed ID: 20190247
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
Bailie GR; Mason NA; Valaoras TG
Hemodial Int; 2010 Jan; 14(1):47-54. PubMed ID: 19888949
[TBL] [Abstract][Full Text] [Related]
17. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease.
Evstatiev R; Alexeeva O; Bokemeyer B; Chopey I; Felder M; Gudehus M; Iqbal T; Khalif I; Marteau P; Stein J; Gasche C;
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):269-77. PubMed ID: 23078888
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of ferric carboxymaltose treatment in children and adolescents with inflammatory bowel disease and other gastrointestinal diseases.
Laass MW; Straub S; Chainey S; Virgin G; Cushway T
BMC Gastroenterol; 2014 Oct; 14():184. PubMed ID: 25326048
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
Onken JE; Bregman DB; Harrington RA; Morris D; Acs P; Akright B; Barish C; Bhaskar BS; Smith-Nguyen GN; Butcher A; Koch TA; Goodnough LT
Transfusion; 2014 Feb; 54(2):306-15. PubMed ID: 23772856
[TBL] [Abstract][Full Text] [Related]
20. Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France.
Toledano A; Luporsi E; Morere JF; Scotté F; Laribi K; Barrière J; Huot-Marchand P; Duvillié L; Concas VH; Bugat R
Support Care Cancer; 2016 Jan; 24(1):67-75. PubMed ID: 25921449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
